Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.46% is 368% above its 5-year average of -16.21%, near the high end of its 5-year range (-155.51%–60.69%).
15.11% above its 12-month average of 37.76%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 31.03%.
EBITDA MARGIN
43.46%
EBITDA MARGIN AVG TTM
37.76%
EBITDA MARGIN AVG 3Y
17.23%
EBITDA MARGIN AVG 5Y
-16.21%
EBITDA MARGIN AVG 10Y
-37.43%
EBITDA MARGIN AVG 15Y
-132.58%
EBITDA MARGIN AVG 20Y
-168.20%
CURRENT VS TTM AVG
+15.11%
CURRENT VS 3Y AVG
+152.25%
CURRENT VS 5Y AVG
+368.13%
CURRENT VS 10Y AVG
+216.12%
CURRENT VS 15Y AVG
+132.78%
CURRENT VS 20Y AVG
+125.84%
Rigel Pharmaceuticals, Inc.
Market Cap
$860.37M
EBITDA Margin
43.46%
TTM Avg
37.76%
3Y Avg
17.23%
5Y Avg
-16.21%
Market Cap
$860.28M
EBITDA Margin
-9.76%
TTM Avg
-14.11%
3Y Avg
-27.72%
5Y Avg
-36.15%
Market Cap
$855.16M
EBITDA Margin
-170.39%
TTM Avg
-102.27%
3Y Avg
-63.10%
5Y Avg
-63.10%
Market Cap
$866.51M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$849.66M
EBITDA Margin
-17.48%
TTM Avg
-35.83%
3Y Avg
-4.31%
5Y Avg
17.66%
Market Cap
$844.84M
EBITDA Margin
-32.91%
TTM Avg
-153.12%
3Y Avg
-170.67%
5Y Avg
-159.26%
Market Cap
$877.07M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$836.98M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
Market Cap
$840.85M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | $860.37M | 43.46% | 37.76% | 17.23% | -16.21% |
| SI-BONE, Inc. (SIBN)vs › | $860.28M | -9.76% | -14.11% | -27.72% | -36.15% |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | -170.39% | -102.27% | -63.10% | -63.10% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $866.51M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | -17.48% | -35.83% | -4.31% | 17.66% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | -32.91% | -153.12% | -170.67% | -159.26% |
| Arbutus Biopharma Corp (ABUS)vs › | $877.07M | -189.51% | -701.94% | -497.69% | -575.23% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.98M | -37.08% | -66.80% | -66.80% | -66.80% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.85M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $837.03M | -68.63% | -68.17% | -9114.49% | -9114.49% |
Gross Margin
91.4%
EBITDA Margin
43.5%
Operating Margin
42.6%
Net Margin
116.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 31.03% |
| 2026-03-31 | 21.22% |
| 2025-12-31 | 34.05% |
| 2025-09-30 | 41.78% |
| 2025-06-30 | 60.69% |
| 2025-03-31 | 25.08% |
| 2024-12-31 | 29.97% |
| 2024-09-30 | 26.52% |
| 2024-06-30 | 2.88% |
| 2024-03-31 | -22.23% |
| 2023-12-31 | 6.31% |
| 2023-09-30 | -14.83% |
| 2023-06-30 | -18.49% |
| 2023-03-31 | -47.44% |
| 2022-12-31 | 4.61% |
| 2022-09-30 | -81.05% |
| 2022-06-30 | -42.68% |
| 2022-03-31 | -155.51% |
| 2021-12-31 | -102.96% |
| 2021-09-30 | -90.63% |
| 2021-06-30 | -48.69% |
| 2021-03-31 | 51.83% |
| 2020-12-31 | -100.93% |
| 2020-09-30 | -74.04% |
| 2020-06-30 | -107.53% |
| 2020-03-31 | 38.02% |
| 2019-12-31 | -111.41% |
| 2019-09-30 | -56.92% |
| 2019-06-30 | -203.38% |
| 2019-03-31 | -144.28% |
| 2018-12-31 | 7.12% |
| 2018-09-30 | -497.66% |
| 2018-06-30 | -1452.27% |
| 2017-09-30 | -1971.44% |
| 2017-03-31 | -448.55% |
| 2016-12-31 | -521.47% |
| 2016-09-30 | -599.07% |
| 2016-06-30 | -155.78% |
| 2016-03-31 | -342.87% |
| 2015-12-31 | -145.36% |
| 2015-09-30 | -49.97% |
| 2015-06-30 | -262.25% |
| 2015-03-31 | -817.54% |
| 2014-12-31 | -264.98% |
| 2013-12-31 | -283.36% |
| 2013-06-30 | -1589.79% |
| 2012-06-30 | -1618.13% |
| 2012-03-31 | -3034.40% |
| 2011-09-30 | -402.64% |
| 2011-06-30 | -5336.96% |
| 2010-12-31 | 15.42% |
| 2010-09-30 | 70.12% |
| 2010-06-30 | 55.14% |
| 2010-03-31 | -676.02% |
| 2009-12-31 | -3300.80% |
| 2007-12-31 | -249.03% |
| 2007-06-30 | -1036.20% |
| 2007-03-31 | -677.08% |
| 2006-12-31 | -526.37% |
| 2006-09-30 | -202.42% |
| 2006-06-30 | -22.90% |
| 2006-03-31 | -95.82% |
| 2005-12-31 | -159.57% |
| 2005-09-30 | -416.33% |
| 2005-06-30 | -268.22% |
| 2005-03-31 | -424.68% |
| 2004-12-31 | -1289.45% |
| 2004-09-30 | -2401.67% |
| 2004-06-30 | -806.32% |
| 2004-03-31 | -840.15% |
| 2003-12-31 | -532.76% |
| 2003-09-30 | -492.06% |
| 2003-06-30 | -406.05% |
| 2003-03-31 | -145.52% |
| 2002-12-31 | -178.70% |
| 2002-09-30 | -241.99% |
